newsfilter
← Latest News
PR Newswire·

Clarivate Announces Sale of Life Sciences & Healthcare Segment for $600 Million

CLVT
  • Clarivate Plc agreed to divest its Life Sciences & Healthcare segment to Altaris LLC for $600 million.
  • The transaction will leave Clarivate focused on its Academia & Government & Intellectual Property segments.
  • Proceeds will be used to reduce debt, improve revenue mix, expand Adjusted EBITDA margins, & lower capital intensity.
  • Clarivate will receive $500 million in cash at closing, $25 million deferred cash, & a $75 million seller note.
  • The deal is expected to close by the end of 2026, subject to regulatory approvals.
  • Clarivate reaffirmed its full-year 2026 financial outlook, including the LS&H segment results classified as discontinued operations in Q3.
  • The company expects to record a non-cash goodwill impairment of $225 million to $250 million on the LS&H segment.
  • Full-year 2026 Adjusted EBITDA is forecasted between $980 million & $1.04 billion with a margin of 42.0% to 43.5%.
  • Full-year 2026 Adjusted diluted EPS is projected to be between $0.70 & $0.80.
  • A conference call & webcast regarding the transaction is scheduled for 9:00 AM Eastern Time on July 6, 2026.